Evofosfamide

Drug Profile

Evofosfamide

Alternative Names: HAP 302; TH-302

Latest Information Update: 04 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Threshold Pharmaceuticals; University of Texas M. D. Anderson Cancer Center
  • Developer Grupo Espanol de Tumores Neuroendocrinos; Merck KGaA; Molecular Templates; Scripps Clinic; Threshold Pharmaceuticals; University of Texas Health Science Center at San Antonio; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Nitroimidazoles; Phosphoramide mustards; Small molecules
  • Mechanism of Action Alkylating agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Soft tissue sarcoma; Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Pancreatic cancer
  • Phase II Biliary cancer; Glioblastoma
  • Phase I Hepatocellular carcinoma; Solid tumours
  • Suspended Leukaemia; Malignant melanoma; Multiple myeloma; Non-small cell lung cancer
  • Discontinued Soft tissue sarcoma

Most Recent Events

  • 02 Aug 2017 Molecular Templates merged with Threshold Pharmaceuticals and the later company changed its name to Molecular Templates
  • 10 May 2017 Phase-I clinical trials in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV) (NCT03098160)
  • 27 Mar 2017 Evofosfamide is still at phase III development stage for Pancreatic cancer in Japan (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top